Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 4.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -94.44M |
| Shares Out | 106.33M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,362,501 |
| Open | 41.83 |
| Previous Close | 41.53 |
| Day's Range | 41.37 - 42.97 |
| 52-Week Range | 1.87 - 48.26 |
| Beta | -0.24 |
| Analysts | Strong Buy |
| Price Target | 48.60 (+14.68%) |
| Earnings Date | Nov 10, 2025 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TERN stock is "Strong Buy." The 12-month stock price target is $48.6, which is an increase of 14.68% from the latest price.
News
Terns CEO Amy Burroughs talks cancer drug trial win
Amy Burroughs, Terns Pharmaceuticals CEO, joins 'Fast Money' to talk its latest cancer drug data
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its prev...
Terns Announces Pricing of Upsized $650 Million Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsi...
Cancer Study Buoys These Small Biotechs
Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.
Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again
Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated super...
Terns Announces Proposed Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a...
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile maint...
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior ...
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CAR...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as ...
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
Terns Pharmaceuticals Inc. (NASDAQ:TERN) stock is trading higher on Monday, with a session volume of 24.36 million, compared to its average volume of 1.31 million, according to Benzinga Pro.
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host inves...
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.
Terns Pharma ends obesity drug program after mid-stage trial data
Terns Pharmaceuticals said on Tuesday it will stop developing its experimental obesity drug after a mid-stage trial showed modest weight loss and raised safety concerns.
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participan...
Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Amy Burroughs - CEO & Director Scott Harris - Ch...
Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript
Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript Company Participants Amy Burroughs - CEO & Director Emil Kuriakose - Chief Medical Officer Scott Harris - Chief Developme...
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-c...
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enr...